comparing cardiovascular and kidney outcomes with tirzepatide vs. glp-1 agonists Beyond glycemia: to analogues | Reviews in Endocrine Metabolic Disorders comparing cardiovascular and kidney outcomes

Despite the short follow-up period, the study adds more evidence to support the hypothesis that GLP-1RAs improve cardiovascular prognosis in patients with T2DM

Lancet (2021) 397(10275):75466

USD 39.95 Prices may be subject to local taxes which are calculated during checkout Similar content being viewed by others References Adler V, Yin Z, Fuchs SY, Benerza M, Rosario L, Tew KD, Pincus MR, Sardana M, Henderson CJ, Wolf CR, Davis RJ and Ronai Z

Outeirino-Iglesias V, Romani-Perez M, Gonzalez-Matias LC, Vigo E, Mallo F (2015) GLP-1 increases preovulatory LH source and the number of mature follicles, as well as synchronizing the onset of puberty in female rats